Alendronic acid/colecalciferol
| Combination of | |
|---|---|
| Alendronic acid | Bisphosphonate |
| Colecalciferol | Vitamin |
| Clinical data | |
| Trade names | Fosamax Plus D, Fosavance, Adrovance, others |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Alendronic acid/colecalciferol, sold under the brand name Fosamax Plus D among others, is a medication for the treatment of osteoporosis in men or in postmenopausal women.[3][2][4][6]
Alendronic acid/colecalciferol was approved for use in the United States and in the European Union in 2005.[7][5]
References
- ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Archived from the original on 29 March 2024. Retrieved 3 April 2024.
- ^ a b "Fosavance Tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 2 March 2020. Retrieved 1 March 2020.
- ^ a b "Fosamax Plus D- alendronate sodium and cholecalciferol tablet". DailyMed. 16 August 2019. Archived from the original on 19 December 2019. Retrieved 1 March 2020.
- ^ a b "Adrovance EPAR". European Medicines Agency (EMA). 26 February 2020. Archived from the original on 2 March 2020. Retrieved 1 March 2020.
- ^ a b "Fosavance EPAR". European Medicines Agency (EMA). 9 October 2019. Archived from the original on 2 March 2020. Retrieved 1 March 2020.
- ^ Von Schacht E, Dambacher MA, Ringe JD, Dukas L (April 2012). "[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence]". MMW Fortschritte der Medizin (in German). 154 (Suppl 1): 10–21. PMID 23427364.
- ^ "Drug Approval Package: Fosamax Plus D (Alendronate Sodium) NDA #021762". U.S. Food and Drug Administration (FDA). 8 June 2006. Archived from the original on 2 March 2020. Retrieved 1 March 2020.